By proceeding, you agree to our Terms of Use and Privacy Policy.
Nicoya is a Canadian biotechnology company dedicated to improving human life by helping scientists succeed.Established in 2012, Nicoya was founded by Ryan Denomme in his relentless pursuit to use nanotechnology to increase the affordability and ease of use of scientific instruments.Within 10 years, Nicoya has grown to a team of 100+ employees who have extensive experience working at the forefront of nanotechnology and biotechnology sectors. Nicoya develops innovative and accessible biosensor technology for in-depth characterization of biomolecular interactions.Alto, the world’s first digital high-throughput benchtop SPR instrument, is capable of accelerating drug discovery using a fraction of sample volume traditionally required for biomolecular interaction analyses. Alto helps biotechnology and pharmaceutical companies go-to-market faster with increased efficiency and success early in their product pipelines.
02-04 October 2023
Join us for the 14th World Bispecific Summit in 2023, where we celebrate the remarkable advancements and immense potential of bispecific antibody treatments. In this pivotal year, bispecific antibody therapies have emerged as formidable contenders in
Event Ended
USA
Paid
Boston
13-16 December 2023
The latest science and research on antibody engineering, design and selection diving into critical topics including Neurodegenerative Diseases, Tumor Microenvironment in Antibody Therapy, Antibody Immune Agonist, Bi-Specifics, ADCs, Protein-Based Deg
Hybrid
San Diego